康希诺生物股份公司 2024 年年度股东大会 证券代码：688185 证券简称：康希诺 康希诺生物股份公司 2024 年年度股东大会会议资料 2025 年 6 月 康希诺生物股份公司 2024 年年度股东大会 | 目录 | | --- | | 年年度股东大会会议须知 | 2024 | 1 | | --- | --- | --- | | 年年度股东大会会议议程 | 2024 | 4 | | 年年度股东大会会议议案 | 2024 | 7 | | 议案一：关于 年度董事会工作报告的议案 | 2024 | 7 | | 议案二：关于 年度监事会工作报告的议案 | 2024 | 14 | | 议案三：关于 年年度报告及摘要的议案 | 2024 | 18 | | 议案四：关于 年度财务决算报告与财务审计报告的议案 | 2024 | 19 | | 议案五：关于 年度利润分配方案的议案 | 2024 | 20 | | 议案六：关于聘请 年度境内外审计机构及内部控制审计机构的议案 2025 | | 21 | | 议案七：关于增发公司 A 股及/或 H 股股份的一般性授权的议案 | | 22 | | 议案八：关于提请股东大会授权董 ...

Core Viewpoint - The performance of A-share vaccine companies remains sluggish in Q1 2025, with over half of the 14 companies reporting a decline in net profit, and the top five companies experiencing a drop of over 80% [1][2]. Industry Overview - The overall trend in the vaccine industry shows a decline in both revenue and profit, attributed to a drop in market demand, policy adjustments, inventory buildup, and difficulties in collecting accounts receivable [1][3]. - The low vaccination rates for self-paid vaccines, such as flu and HPV vaccines, are identified as a core reason for the decline in performance [2][3]. Company Performance - Leading companies like Wantai Biological Pharmacy (万泰生物) reported a revenue of 401 million yuan, down 46.76%, and a net loss of 52.78 million yuan; Zhifei Biological Products (智飞生物) saw a revenue drop of 79.16% to 2.374 billion yuan, with a net loss of 305 million yuan; Watson Bio (沃森生物) reported a revenue decline of 22.93% to 462 million yuan, with a non-recurring net loss of 11.49 million yuan [1][2]. Market Dynamics - The competition in the HPV vaccine market has intensified, particularly after the age eligibility for the nine-valent HPV vaccine was expanded, negatively impacting sales for companies like Wantai and Zhifei [2]. - The changing population structure, with a decline in newborns, has reduced demand for traditional childhood vaccines, while the adult vaccine market remains underdeveloped [2][3]. Financial Challenges - Companies are facing increased financial pressure due to inventory buildup and difficulties in accounts receivable collection, with Wantai reporting impairment losses of 51.33 million yuan and Zhifei reporting 38.34 million yuan [3][4]. - Price wars are exacerbating the situation, with significant price reductions in both HPV and flu vaccine markets, leading to further profit compression [3][4]. Strategic Responses - Some companies, like Watson Bio and CanSino, are actively seeking new growth avenues through international expansion, product upgrades, and government collaborations [4][5]. - Watson Bio's overseas revenue reached nearly 300 million yuan in H1 2024, marking a 98% increase, and its dual-valent HPV vaccine received pre-certification from the WHO [5][6]. Future Outlook - The vaccine industry is expected to undergo accelerated differentiation, with companies possessing technological reserves and global strategies, like Watson Bio and CanSino, likely to emerge stronger [6][7]. - Addressing public vaccine hesitancy remains a significant challenge, necessitating collaboration with healthcare institutions to enhance public awareness and vaccination rates, particularly among chronic disease patients [6][7].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 2025年4月30日 狀態: 新提交 | | --- | | 截至月份: | 致：香港交易及結算所有限公司 公司名稱: 康希諾生物股份公司 呈交日期: 2025年5月8日 I. 法定/註冊股本變動 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | H | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06185 | 說明 | H 股 | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | 已發行股份總數 | | | 上月底結存 | | | 132,670,900 | 0 | | 132,670,900 | | 增加 / 減少 (-) | | | 0 | 0 | | | | 本月底結存 | | | 132,670,900 | 0 | | 132,670,900 | | 1. 股份分類 | 普通股 | 股份類別 | H | ...

Core Viewpoint - 康希诺 has shown significant improvement in its financial performance, with a notable reduction in losses and a positive revenue growth trajectory, indicating a potential recovery from the impacts of the COVID-19 pandemic [2][3][4]. Financial Performance - In Q1 2025, 康希诺 reported revenue of 1.074 billion yuan, a year-on-year increase of 20.02%, while the net loss attributable to shareholders was 11.55 million yuan, down from a loss of 170 million yuan in the same period last year [2]. - The company achieved a substantial reduction in losses due to several factors, including the absence of one-time special losses from the previous year, increased market share of its meningococcal products, and additional government subsidies [2][4]. - For the full year 2024, 康希诺's revenue grew by 137.01% to 846 million yuan, with a narrowed net loss of 379 million yuan [3]. Market Position and Competitiveness - 康希诺's performance stands out in a challenging vaccine market, where most domestic vaccine manufacturers reported declines in revenue [4][3]. - The company’s meningococcal vaccine, 曼海欣, has become a key revenue driver, contributing significantly to its Q1 2025 revenue [7][10]. - Despite the overall decline in the meningococcal vaccine market, 康希诺's products have shown growth, with 曼海欣's approval and sales expected to continue expanding [9][10]. Product Pipeline and Future Prospects - 康希诺 has two approved meningococcal vaccines, with 曼海欣 being the primary revenue contributor, and is actively pursuing market expansion both domestically and internationally [6][10]. - The company is also awaiting approval for its 13-valent pneumococcal conjugate vaccine, which could further enhance its product portfolio, although competition in this segment is strong [11]. - The future growth potential of 康希诺 remains uncertain, as its current and upcoming products may not provide significant long-term growth opportunities [11].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688185 证券简称：康希诺 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 ■ (二)非经常性损益项目和金额 √适用 □不适用 单位：元 币种：人民币 ■ 对公司将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号一一非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 (三)主要会计数据、财务指标发生变动的情况、原因 √适用 □不 ...

Group 1 - The A-share market shows a mixed performance with the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index experiencing strong fluctuations [1] - The Sci-Tech Biomedicine Index ETF (588700) rose by 1.26% with a turnover rate of 4.66% and a trading volume exceeding 11 million yuan, indicating active trading [1] - The ETF closely tracks the Sci-Tech Biomedicine Index, which includes 50 large-cap companies in biomedicine, biomedical engineering, biopharmaceuticals, and other related sectors [1] Group 2 - The pharmaceutical sector has undergone a prolonged adjustment, with overall valuations at low levels and public fund holdings being underweight, suggesting potential for recovery [1] - The medical sector is highlighted as a key investment direction due to its strong safety profile amid international uncertainties and the continuous realization of catalysts for innovative drugs [2] - There are structural opportunities in the pharmaceutical sector, particularly with the integration of artificial intelligence in diagnostics and medical services, which may lead to sustained valuation improvements [1]

康希诺生物股份公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 证券代码：688185 证券简称：康希诺 公告编号：2025-014 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 6 月 4 日 13 点 30 分 召开地点：天津市河东区卫国道 126 号天津东凯悦酒店二层悦宾厅 1 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 4 日 至2025 年 6 月 4 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 股东大 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 137,160,578.06, representing a year-over-year increase of 20.02% compared to CNY 114,282,281.78 in the same period last year[4]. - The net loss attributable to shareholders for the period was CNY 11,545,431.51, a significant improvement from a loss of CNY 170,095,866.61 in the previous year[4]. - Total operating revenue for Q1 2025 was ¥137,160,578.06, an increase of 20.00% compared to ¥114,282,281.78 in Q1 2024[18]. - Net profit for Q1 2025 was a loss of ¥11,545,431.51, an improvement from a loss of ¥174,882,984.28 in Q1 2024[19]. - The total comprehensive loss for Q1 2025 was ¥11,549,283.95, an improvement from a loss of ¥174,560,182.55 in Q1 2024[19]. Cash Flow - The net cash flow from operating activities was a net outflow of CNY 13,801,882.53, which is an improvement of CNY 94,393,791.82 compared to the previous year's outflow[7]. - Cash flow from operating activities showed a net outflow of ¥13,801,882.53 in Q1 2025, compared to a net outflow of ¥108,195,674.35 in Q1 2024[21]. - Cash flow from investing activities resulted in a net outflow of ¥437,359,085.65 in Q1 2025, contrasting with a net inflow of ¥275,011,228.44 in Q1 2024[22]. - Cash and cash equivalents at the end of Q1 2025 were ¥1,055,668,836.98, down from ¥2,374,907,374.57 at the end of Q1 2024[22]. Research and Development - Research and development (R&D) expenses totaled CNY 88,924,234.66, a decrease of 28.48% from CNY 124,328,450.39 in the same period last year, with R&D expenses accounting for 64.83% of revenue, down 43.96 percentage points[4][7]. - Research and development expenses were ¥72,712,590.56 in Q1 2025, down 25.00% from ¥96,745,611.33 in Q1 2024[18]. - The company continues to focus on enhancing R&D efficiency and integrating resources across different pipelines to drive future growth[7]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 7,820,387,409.65, a decrease of 1.73% from CNY 7,958,132,235.38 at the end of the previous year[5]. - The company's current assets totaled CNY 4,134,286,329.53, down from CNY 4,282,490,715.65, indicating a decrease of about 3.45%[13]. - The company's total liabilities were CNY 2,921,615,159.54, down from CNY 3,048,260,581.65, showing a reduction of around 4.17%[15]. - The total equity attributable to the owners of the parent company was CNY 4,898,772,250.11, slightly decreasing from CNY 4,909,871,653.73, a change of about 0.23%[15]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,828[9]. - The company has not reported any significant changes in its major shareholders or their participation in margin trading activities[11]. Profitability Metrics - The weighted average return on equity improved by 3.04 percentage points to -0.24% from -3.28% in the previous year[4]. - The company's gross profit margin improved by 23.14 percentage points due to optimized production capacity and cost control measures[7]. - The company's inventory increased to CNY 322,559,055.80 from CNY 283,414,610.09, marking an increase of approximately 13.80%[13]. - The company's short-term borrowings decreased to CNY 213,622,195.45 from CNY 377,348,417.32, a reduction of about 43.45%[15]. - The company's long-term borrowings increased to CNY 1,114,926,712.74 from CNY 1,098,538,320.81, reflecting an increase of approximately 1.49%[15].

Core Viewpoint - The impact of the U.S. tariff policy on Chinese pharmaceutical companies is relatively limited, with many companies reporting normal operations and minimal effects from the tariffs [1][2][3][4][5]. Company Responses - Heng Rui Pharmaceutical stated that overseas sales account for only 2.56% of its revenue, indicating that U.S. tariffs will have a minimal impact on its business [1]. - Han Yu Pharmaceutical emphasized its diversified market layout, which mitigates risks from single market policy changes, and reported no significant impact from the tariffs [2]. - WuXi AppTec acknowledged that tariffs would have some effect but deemed it manageable, highlighting their optimized supply chain and global presence [3]. - Kang Tai Biological reported no exports to the U.S. and is focusing on markets along the Belt and Road, indicating a strategic shift to other regions [4]. - Mindray Medical confirmed that while some raw materials are imported from the U.S., they are taking measures to ensure supply safety and view the tariff impact as a one-time issue [4]. Industry Trends - The Chinese vaccine industry is rapidly developing, with companies like CanSino Biologics transitioning from followers to leaders in vaccine technology, focusing on domestic innovation [6][7]. - The overall sentiment among companies is that the tariff policy presents an opportunity for domestic product substitution, with many firms prepared to adapt to changing market conditions [5][8]. - Companies are increasingly focusing on technological innovation and expanding into emerging markets to counteract potential supply chain disruptions caused by tariffs [5][6][7].

Financial Performance - The company reported a basic earnings per share of -0.0500 yuan for Q1 2025, a significant improvement of 92.75% compared to -0.6900 yuan in Q1 2024 [1] - Revenue for Q1 2025 was 1.37 billion yuan, representing a 20.18% increase from 1.14 billion yuan in Q1 2024 [1] - The net profit for Q1 2025 was -0.12 billion yuan, showing a 92.94% improvement from -1.7 billion yuan in Q1 2024 [1] - The return on equity for Q1 2025 was -0.24%, a notable improvement from -3.28% in Q1 2024 [1] Shareholder Information - The top ten unrestricted shareholders collectively hold 17,638.31 million shares, accounting for 71.28% of the circulating shares, with a decrease of 81.52 million shares compared to the previous period [2] - HKSCC NOMINEES LIMITED remains the largest shareholder with 9,785.73 million shares, representing 39.55% of the total share capital [3] - The advanced manufacturing industry investment fund (limited partnership) saw a decrease of 81.52 million shares [3] Dividend Distribution - The company has announced that there will be no distribution or transfer of dividends this time [4]